Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.According to University of Pennsylvania School of Veterinary Medicine researchers, a cytokine messenger protein called interleukin-27 acts as a gatekeeper for many chronic inflammatory diseases.
Subscribe to our email newsletter
The Penn researchers found that IL-27 inhibits the immune system cells responsible for an array of inflammatory-related diseases, including encephalitis, arthritis, Crohn’s disease, and lupus.
Their findings, which appear in the online edition of Nature Immunology, suggest that IL-27 may be a useful target for treating a number of autoimmune diseases. The researchers believe that restoring or augmenting the abilities of IL-27 may be enough to halt inflammation.
In previous studies, the researchers found that the IL-27 cytokine limits the duration and intensity of white blood activation. Prior to their research, it was generally assumed that IL-27 promoted inflammation.
The findings open up the possibility that strategies that augment the effectiveness of IL-27 can be used therapeutically. The researchers suggest that the best route might be through using p28, a small active portion of the IL-27 molecule.
“It may be possible to use IL-27 or its active subunit in such a way that we can temper the immune system without suppressing the beneficial immune reactions,” noted Christopher Hunter, a professor in Penn School of Veterinary Medicine’s department of pathobiology.